Junin Virus Vaccines

  • D. A. Enria
  • J. G. Barrera Oro
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 263)

Abstract

Argentine hemorrhagic fever (AHF) was recognized as a new clinical entity from the richest farming region of Argentina in the 1950s (Arribalzaga 1955). The etiologic agent of this disease, Junin virus (JUN), was isolated in 1958 (Parodi et al. 1958; Piroski et al. 1959). JUN belongs to the Arenaviridae family, which includes other rodent-borne pathogens which are important causes of hemorrhagic fever in Africa, (Lassa) and South America (Machupo, Guanarito, and Sabia viruses). The Arenaviridae comprises at least 20 recognized members. Arenaviruses are enveloped RNA viruses, and are divided into two groups, with low level antigenic relatedness: the Old World group, and New World group or Tacaribe complex. Two antigenic subgroups were defined within the New World arenaviruses. JUN is contained into the first group, together with Amapari, Latino, Machupo and Tacaribe viruses. Phylogenetic analysis have shown that Old World and New World arenaviruses occupied two distinct clades, and that New World arenaviruses comprise three evolutionary lineages, named A, B, and C. JUN is contained in lineage B, together with the other three agents causing South American hemorrhagic fevers (Enria et al. 1999a).

Keywords

Hemorrhagic Fever Protective Efficacy Geometric Mean Titer Lassa Fever Secondary Seed 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agnese G (1999) Histaria de una enfermedad, imaginario y espacio rural: La fiebre hemorrágica argentina — 1943–1963. Tesis para optar al grado de Licenciatura en Histaria. 5.2. Experiencias en el Hospital Neuropsiquiátrico. Pontificia Universidad Catolica Argentina. Facultad de derecho y Ciencias Sociales. Instituto de Historia. Rosario. Argentina.Google Scholar
  2. Albariño CJ, Ghiringhelli PD, Posik DM, et al. (1997) Molecular characterization of attenuated Junin virus strains. J Gen Virol 78: 1605–1610PubMedGoogle Scholar
  3. Alibek K (1999) Biohazard. Biodefense (Junin virus: pp. 42, 113, 126, 202, 281; Machupo virus: pp. 18, 42, 113, 118, 126, 202, 234, 281). Random House, New York, NYGoogle Scholar
  4. Arribalzaga RA (1955) Una nueva enfermedad epidémica a germen desconocido: hipertermia nefrotóxica, leucopénica y enantemética. Día Médico 27:1204–1210PubMedGoogle Scholar
  5. Auperin DD, Esposito JJ, Lange JV, et al. (1988) Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from lethal Lassa virus infection. Virus Res 9:233–248PubMedCrossRefGoogle Scholar
  6. Avila MM, Samoilovich SR, Weissenbacher MC (1979) Infección del cobayo con la cepa atenuada del virus Junin XJCI3. Medicina (B. Aires) 39:597–603Google Scholar
  7. Avila MM, Laguens RM, Laguens RP, et al. (1981) Selectividad tisular e indicadores de virulencia de tres cepas del virus Junin. Medicina (B. Aires) 41:157–166Google Scholar
  8. Avila MM, Frigerio MJ, Weber EL, et al. (1985) Attenuated Junin virus infection in Callithrix jacchus. J Med Virol 15:93–100PubMedCrossRefGoogle Scholar
  9. Barrera Oro JG, Girola RA, Frugone G (1967) Estudios inmunológicos con virus Junin: II. inmunidad adquirida por cobayos inoculados con virus inactivado por formol. Medicina (B. Aires) 27:279–282Google Scholar
  10. Barrera Oro JG and Eddy GA (1982) Characteristics of Candidate live attenuated Junin Virus Vaccine. IV International Conference on Comparative Virology, Banff, Alberta, Canada. Abstract S4–10Google Scholar
  11. Barrera Oro JG, McKee KT Jr, Kuehne AI, et al. (1985) Preclinical trials of a live, attenuated Junin virus vaccine in rhesus macaques. Institut Pasteur Symposium on Vaccines and Vaccinations. Paris, France. Abstract P28Google Scholar
  12. Barrera Oro J, MacDonald C, Kenyon R, et al. (1987) Virus isolation and immune response in humans inoculated with a live-attenuated Junin virus (JV) vaccine. VIIth International Congress of Virology. Edmonton, Alberta, Canada. Abstract R3.45Google Scholar
  13. Barrera Oro JG, Lupton HW, Jahrling PB, et al. (1988) Cross protection against Machupo virus with Candid #1 live-attenuated Junin virus vaccine. I. The post-vaccination prechallenge immune response. Second International Conference on Comparative Virology, Mar del Plata, Argentina. Abstract P.E.1Google Scholar
  14. Barrera Oro JG, McKee KT Jr (1992) Hacia una vacuna contra la Fiebre Hemorrágica Argentina. Bol of Sanit Panam 112:296–305Google Scholar
  15. Boxaca MC, Guerrero LB de, Weber L, Malumbres E (1981) Protección inducida en cobayo por la variente XJ0 del virus Junin. Medicina (B. Aires) 41:25–34Google Scholar
  16. Boxaca MC, Guerrero LB, de Malumbres E (1984) Modification of Junin virus neurotropism in the guinea pig model. Acta Virol 28:198–203PubMedGoogle Scholar
  17. Carballal G, Cossio PM, de la Vega MI, et al. (1982) Neurovirulencia de la cepa XJCI3, de virus Junin en un primate sudamericano. Tercer Congreso de Microbiología, Córdoba, Argentina, Compendio 186Google Scholar
  18. Carballal G, Videla C, Oubiña JR, et al. (1985) Antigenos inactivados de virus Junin. Medicina (B. Aires) 45: 153–158Google Scholar
  19. Casals J (1965) Serological studies on Junin and Tacaribe viruses. Am J Trop Med Hyg 14:794–795PubMedGoogle Scholar
  20. Clegg JC, Lloyd G (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever. Lancet 2(8552):186–188PubMedCrossRefGoogle Scholar
  21. Contigiani MS, Sabattini MS (1977) Virulencia diferencial de cepas de virus Junin por marcadores biológicos en ratones y cobayos. Medicina (B. Aires) 37:244–251Google Scholar
  22. Coto CE, Damonte EB, Calello MA, et al. (1980) Protection of guinea pigs inoculated with Tacaribe virus against lethal doses of Junin virus. J Infect Dis 141:389–393PubMedCrossRefGoogle Scholar
  23. Cresta B, Padula P, de Martinez Segovia ZM (1980) Biological properties of Junin virus proteins: I, identification of the immunogenic glycoprotein. Intervirology 13:284–288PubMedCrossRefGoogle Scholar
  24. D’Aiutolo AC, Lampuri JS, Coto CE (1979) Reactivación del virus Junin inactivado por la luz ultravioleta. Medieina (B. Aires) 39:801Google Scholar
  25. Damonte EB, Calello MA, Coto CE, et al. (1981) Inmunización de cobayos contra la fiebre hemorrágica argentina con virus Tacaribe replicado en células diploides humanas. Medicina (B. Aires) 41:467–470Google Scholar
  26. Damonte EB, Mersich SE, Candurra NA, et al. (1986) Cross reactivity between Junin and Tacaribe viruses as determined by neutralization test and immunoprecipitation. Med Microbiol Immunol 175:85–88PubMedCrossRefGoogle Scholar
  27. Downs WG, Anderson CR, Aitken THG, et al. (1963) Tacaribe virus, a new agent isolated from Artibeus bats and mosquitoes in Trinidad. Am J Trop Med Hyg 12:639–646Google Scholar
  28. Eddy GA, and Barrera Oro JG (1977) Discusión general. Medicina (B. Aires) 37(Supl 3):257–259Google Scholar
  29. Enria DA, Briggiler AM, Fernández NJ, et al. (1984) Importance of dose of neutralizing antibodies in treatment of Argentine hemorrhagic fever with immune plasma. Lancet 8397:255–256CrossRefGoogle Scholar
  30. Enria DA, Damilano AJ, Briggiler AM, et al. (1985) Síndrome neurológico tardío en enfermos de Fiebre Hemorrágica Argentina tratados con plasma inmune. Medicina (B. Aires) 45(6):615–620Google Scholar
  31. Enria DA, Maiztegui JI (1994) Antiviral treatment of Argentine hemorrhagic fever. Antivir Res 23:23–31PubMedCrossRefGoogle Scholar
  32. Enria DA, Briggiler AM, Feuillade MR (1998) An overview of the epidemiological, ecological and preventive hallmarks of Argentine Hemorrhagic Fever (Junin virus). Bull Inst Pasteur 96: 103–114CrossRefGoogle Scholar
  33. Enria D, Bowen M, Mills JN, et al. (1999a) I Arenaviruses. In: Guerrant RL, Walker DH, Weller PF, Saunders WB (eds) Tropical Infectious Diseases: Principles, Pathogen & Practice. New York, pp 1189–1212Google Scholar
  34. Enria DA, Feuillade MR, Levis SC, et al. (1999b) Impact of vaccination of a high risk population for Argentine hemorrhagic fever with a live attenuated Junin virus vaccine. In: Saluzzo JF., Dodet B (eds) Factors in the Emergence and Control of Rodent-borne Viral Diseases. Elsevier SAS, Paris, France, pp 273–280Google Scholar
  35. Farrington CP (1993) Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 22:742–746PubMedCrossRefGoogle Scholar
  36. Feuillade MR, Sabattini M, Enria D (1997) Vacunación de una poblacion expuesta a riesgo natural de adquirir la fiebre hemorragica Argentina. Evolucion de la incidencia. V Congreso Latinoamericano de Medicina Tropical. 3–7 March 1997, Havana, Cuba, Abstracts:650Google Scholar
  37. Fisher-Hoch SP, McCormick JB, Auperin DD, et al. (1989) Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Nat Acad Sci USA 86:317–321PubMedCrossRefGoogle Scholar
  38. García J, Calderón G, Sabattini M, et al. (1996) Infección por virus Junin (VJ) de Calomys musculinus (Cm) en áreas con diferente situación epidemiológica para la Fiebre Hemorrágica Argentina (FHA). Medicina (B. Aires) 56:624Google Scholar
  39. Ghiringhelli PD, Albarino CG, Piboul I, Romanowski V (1997) The glycoprotein precursor gene of the attenuated Junin Virus vaccine strain (Candid #1). Am J Trop Med Hyg 56(2):216–225PubMedGoogle Scholar
  40. Guerrero LB, de, Weissenbacher MC, Parodi AS (1969) Inmunización contra la fiebre hemorrágica argentina con una cepa atenuada del virus Junin; I: estudio de una cepa modificada del virus Junin, inmunización de cobayos. Medicina (B. Aires) 29: 1–5Google Scholar
  41. Guerrero LB (1977) Vacunas experimentales contra la fiebre hemorragica Argentina. Medicina (B. Aires) 37:252–259Google Scholar
  42. Guerrero LB de, Boxaca MC (1980) Estudio preliminar de una variante atenuada del virus Junin derivada de la cepa prototipo XJ. Medicina (B. Aires) 40:267–274Google Scholar
  43. Guerrero LB de, Boxaca MC, Rabinovich RD, et al. (1983) Evolución de la infección en cobayos infectados con la variante atenuada XJ0 del virus Junin. Rev Argent Microbiol 15:205–212PubMedGoogle Scholar
  44. Guerrero LB de, Boxaca MC, Malumbres E, et al. (1985) Pathogenesis of attenuated Junin virus in the guinea pig model. J Med Virol 15: 197–202PubMedCrossRefGoogle Scholar
  45. Jahrling PB, Trotter RW, Barrera Oro JG, et al. (1988) Cross-protection against Machupo virus with Candid #1 Junin virus vaccine: III. post-challenge clinical findings. Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region, Mar del Plata, Argentina, abstract PE3Google Scholar
  46. Kenyon RH, McKee K, Barrera Oro JG, et al. (1989) Protective efficacies in rhesus monkeys of Candid 1 strain Junin virus (JV) and Tacaribe virus against aerosol challenge with virulent JV: 38th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Honolulu. Abstract 136Google Scholar
  47. Kurstak E (1994) Modern vaccinology: Progress towards the global control of Infectious Diseases. In:Kurstak E (ed) Modern Vaccinology, Plenun Medical Book Company, New York, London, pp 1–9Google Scholar
  48. Laguens RM, Avila MM, Samoilovich SR, et al. (1983) Pathogenicity of an attenuated strain (XJCI3) of Junin virus: morphological and virological studies in experimentally infected guinea pigs. Intervirology20: 195–201PubMedCrossRefGoogle Scholar
  49. López N, Scolaro L, Rossi C, et al. (2000) Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J Gen Vir: 1273–1281Google Scholar
  50. Lupton HW, Jahrling PB, Barrera Oro JG, et al. (1988) Cross-protection against Machupo virus with Candid #1 live-attenuated Junin virus vaccine: II, post-challenge virological and immunological findings. Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region, Mar del Plata, Argentina, abstract PE2Google Scholar
  51. MacDonald C, McKee K, Peters C, et al. (1987) Initial clinical assessment of humans inoculated with a live-attenuated Junin virus vaccine. In: Programs and abstracts of the VII International Congress of Virology (Edmonton, Canada). Abstract R3.27Google Scholar
  52. MacDonald C, McKee K, Meegan J, et al. (1988) Initial evaluation in humans of a live-attenuated vaccine against Argentine hemorrhagic fever. In: Proceedings of the XVI Army Science Conference (Hampton, Virginia). US ArmyGoogle Scholar
  53. McKee KT, Jr, Barrera Oro JG, Kuchne AI, et al. (1992) Candid No 1 Argentine Hemorrhagic Fever vaccine Protects Against Lethal Junin Virus Challenge in Rhesus Macaques. Intervirology 34:154–163PubMedCrossRefGoogle Scholar
  54. McKee KT Jr, Green DE, Mahlandt BG, et al. (1985) Infection of Cebus monkeys with Junin virus.Medicina (B. Aires) 45:144–152Google Scholar
  55. Maiztegui JI, and Sabattini MS (1977) Extensión progresiva del área endémica de Fiebre hemorrrágica argentina. Medicina (B. Aires) 37:162–166Google Scholar
  56. Maiztegui JI, Fernández NJ, Damilano AJ, (1979) Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and late neurological syndrome. Lancet8154: 1216–1217CrossRefGoogle Scholar
  57. Maiztegui JI, Feuillade MR, Briggiler AM (1986) Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Inmunol 175: 149–152CrossRefGoogle Scholar
  58. Maiztegui J, Levis S, Enria D, et al. (1988) Inocuidad e inmunogenicidad en seres humanos de la cepa Candid 1 de virus Junin. Medicina (B. Aires) 6:660Google Scholar
  59. Maiztegui JI, McKee KT Jr (1989) Inoculation of human volunteers with a vaccine against Argentine hemorrhagic fever. In: Program and abstracts of the VI International Conference on Comparative and Applied Virology (Banff. Canada). Abstract S4Google Scholar
  60. Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. (1998) Protective efficacy of a live attenuated vaccine against Argentine Hemorrhagic Fever. J Infect Dis 177:277–283PubMedCrossRefGoogle Scholar
  61. Malumbres E, Boxaca MC, Guerrero LB de, et al. (1984) Persistence of attenuated Junin virus strains in guinea pigs infected by IM or IC routes. J Infect Dis 149:1022PubMedCrossRefGoogle Scholar
  62. Martinez Segovia ZM de, Arguelles G, Tokman A (1980) Capacidad antigénica del virus Junin inactivado mediante oxidación fotodinámica. Medicina (B. Aires) 40:156–160Google Scholar
  63. Mettler NE, Casals J, Shope RE (1963) Study of the antigenic relationships between Junin virus. the etiological agent of Argentinean hemorrhagic fever, and other arthropod-borne viruses. Am J Trop Med Hyg 12:647–652Google Scholar
  64. Mettler N (1969) Argentine hemorrhagic fever: current knowledge. PAHO Scientific Publication 183, Washington DC, Pan American Health Organization.Google Scholar
  65. Mills IN, Ellis BA, McKee KT, et al. (1992) A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am J Trop Med Hyg 47:749–763PubMedGoogle Scholar
  66. Morrison HG, Bauer SP, Lange JV, et al. (1989) Protection of guinea pigs from Lassa fever byvaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 171:179–188PubMedCrossRefGoogle Scholar
  67. Parodi AS, Geenway DJ, Rugiero HR, et al. (1958) Sobre la etiología del brote epidemico de Junin. Día Médico 30:2300–2301PubMedGoogle Scholar
  68. Parodi AS, Coto CE (1964) Inmunización de cobayos contra el virus Junin por inoculación del virus Tacaribe. Medicina (B. Aires) 24:151–153Google Scholar
  69. Parodi AS, de Guerrero LB, Weissenbacher M (1965) Fiebre hemorrágica argentina: vacunación con virus Junin inactivado. Ciencia e Investigación 21:132–133Google Scholar
  70. Pirosky I, Martini P, Zuccarini J, et al. (1959) Virosis hemorrágica del noroeste bonaerense (endemoepidímica, febril, exantemática y leucopínica): V. la vacuna específica y la vacunación. Orientación Médica 8:743–744Google Scholar
  71. Rico-Hesse R (1999) Vaccines for emergent American arenaviruses. In: Saluzzo JB, Dodet B (eds) Factors in the emergence and control of rodent-borne viral diseases. Editions scientifiques et medicales Elsevier SAS, pp 267–272Google Scholar
  72. Rugiero HA, Astarloa L, Gonzalez Cambaceres C, et al. (1969) Inmunización contra la fiebre hemorrágica argentina con una cepa atenuada de virus Junin: II, inmunización de voluntarios, análisis clínico y del laboratorio. Medicina (B. Aires) 29:81–92Google Scholar
  73. Rugiero HA, Magnoni C, Cintora FA, et al. (1974) Inmunización contra la fiebre hemorrágica argentina con una cepa atenuada de virus Junin: análisis de 636 vacunados. Pren Med Argent 61:231–240Google Scholar
  74. Rugiero HA, Magnoni C, Guerrero LB de, et al. (1981) Persistence of antibodies and clinical evaluation in volunteers 7 to 9 years following the vaccination against Argentine hemorrhagic fever. J Med Virol 7:227–232CrossRefGoogle Scholar
  75. Sabattini MS and Contigiani MS (1982) Ecological and biological factors influencing the maintenance of arenaviruses in nature, with special reference to the agent of Argentine hemorrhagic fever. In: Pinheiro FD (ed) International Symposium on Tropical Arbovirus and Hemorrhagic Fevers, Academia Brasilera de Ciencias, Rio de Janeiro, pp 251–262Google Scholar
  76. Samoilovich SR, Pecci Saavedra J, Frigerio MJ, et al. (1984) Nasal and intra thalamic inoculations of primates with Tacaribe virus: protection against Argentine hemorrhagic fever and absence of neurovirulence. Acta Virol 28:277–281PubMedGoogle Scholar
  77. Samoilovich SR, Calello MA, Laguens RP, et al. (1988) Long-term protection against Argentine hemorrhagic fever in Tacaribe virus infected marmosets: virologic and histopathologic findings. J Med Virol 24:229–236PubMedCrossRefGoogle Scholar
  78. Tauraso N, Shelokov A (1965) Protection against Junin virus by immunization with live Tacaribe virus. Proc Soc Exp Biol Med 119:608–611PubMedGoogle Scholar
  79. US Food and Drug Administration’s Invcstigational New Drug Application #2257Google Scholar
  80. Videla C, Carballal G, Remorini P, et al. (1989) Formalin inactivated Junin virus: immunogenicity and protection assays. J Med Virol 129:215–220CrossRefGoogle Scholar
  81. Wallen KH (1963) Demonstration of inapparent heterogeneity in a population of an animal virus by single-burst analyses. Virology 20:230–234CrossRefGoogle Scholar
  82. Weissenbacher M, Guerrero LB, de, Help G, et al. (1969) Inmunización contra la fiebre hemorrágica argentina con una cepa atenuada de virus Junin: III, reacciones serológicas en voluntarios. Medicina (B. Aires) 29:88–92Google Scholar
  83. Weissenbacher MC, Coto CE, Calello MA (1975) Cross-protection between Tacaribe complex viruses: presence of neutralizing antibodies against Junin virus (Argentine hemorrhagic fever) in guinea pigs infected with Tacaribe virus. Intervirology 6:42–49PubMedCrossRefGoogle Scholar
  84. Weissenbacher MC, Coto CE, Calello MA, et al. (1982) Cross-protection in non-human primates against Argentine hemorrhagic fever. Infect Inmun 35:425–430Google Scholar
  85. Weissenbaeher MC, Damonte EB (1983) Fiebre hemorrágica argentina. Ade Microbiol Enf Infect 2: 119–171Google Scholar
  86. Weissenbacher MC, Laguens RP, Coto CE (1987) Argentine hemorrhagic fever. Curr Top Microbiol Immunol 134:79–116PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • D. A. Enria
    • 1
  • J. G. Barrera Oro
    • 2
    • 3
  1. 1.Instituto Nacional de Enfermedades Virales Humanas (INEVH) “Dr. Julio I. Maiztegui”PergaminoArgentina
  2. 2.Instituto MalbranCONICETArgentina
  3. 3.The Salk InstituteUSA

Personalised recommendations